Review of Evidence for Treatment of Methamphetamine Use Disorder | August 16, 2022
Date of Presentation: August 16, 2022
Type: Past Presentation
Audience: Clinical
Program: Advancing Pharmacist Roles in Substance Use Disorder Treatment and Recovery Teams ECHO Program
Keywords: #contingency #contingency management #meth #methamphetamine #MUD #psychosocial #stimulant #SUD #use disorder
In this presentation, Dr. Jasen Christensen, DO, provides an overview of the existing evidence for treatment and management of methamphetamine use disorder (MUD). Dr. Christensen describes the strength of evidence for psychosocial interventions and use of specific medications for MUD.
Recording:
Presented by:
Dr. Jasen Christensen, DO
Dr. Jasen Christensen, DO, is a psychiatrist at the University of New Mexico Hospital.
Resources Provided:
- To Claim CPE
- Treatment of Stimulant Use Disorders (SAMHSA)
- Randomized controlled trial of contingency management for stimulant use in community mental health patients with serious mental illness
- Mirtazapine to reduce methamphetamine use: a randomized controlled trial
- Effects of Mirtazapine for Methamphetamine Use Disorder Among Cisgender Men and Transgender Women Who Have Sex With Men: A Placebo-Controlled Randomized Clinical Trial
- Bupropion for the treatment of methamphetamine dependence
- Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence
- Bupropion and Naltrexone in Methamphetamine Use Disorder
- Aripiprazole for the treatment of methamphetamine dependence: a randomized, double-blind, placebo-controlled trial
- Pharmacotherapy for Stimulant-Related Disorders
- Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder
- Recovery Incentives: California's Contingency Management Program
- Pharmacist Toolkit: Methamphetamine Use Disorder
Date added: August 15, 2022
